Genomic DNA and glutathione

Genomic DNA and glutathione represent the molecular components involved in the conditioning regimen required for the successful engraftment of atidarsagene autotemcel (OTL-200), a gene therapy for metachromatic leukodystrophy (EMA, 2020). In this clinical context, genomic DNA serves as the primary target for myeloablative alkylating agents, most commonly busulfan, which creates marrow space by inducing DNA cross-linking and cell death in endogenous hematopoietic stem cells (StatPearls, 2023). Glutathione is the essential tripeptide required for the metabolic detoxification of busulfan via glutathione S-transferase-mediated conjugation (Hassan et al., 1996). The balance between DNA damage and glutathione-mediated clearance determines the intensity of the conditioning and the subsequent success of the OTL-200 cell engraftment. Proper management of this interaction is critical, as insufficient DNA alkylation may lead to graft failure, while excessive busulfan levels due to glutathione depletion can cause severe hepatic and systemic toxicity (PubChem, CID 2478). Consequently, this interaction is a pharmacological pivot point for enabling the therapeutic efficacy of autologous ex vivo gene therapies. Monitoring busulfan exposure through Area Under the Curve (AUC) measurements is the standard clinical practice to ensure the safety and efficacy of this conditioning process (EMA, 2020). This target system highlights the importance of host-environment preparation in the success of advanced genetic medicines.

Other names

Genomic DNA and glutathione – indirect enabling of OTL-200 engraftmentBusulfan-DNA-Glutathione axisConditioning-related DNA alkylation and GSH conjugation

Busulfan mediates myeloablation by alkylating genomic DNA, primarily at the N7 position of guanine, leading to interstrand cross-linking and apoptosis (StatPearls, 2023). Glutathione acts as a nucleophilic substrate that conjugates with busulfan via glutathione S-transferases, facilitating its excretion and protecting non-target tissues from excessive alkylation (Hassan et al., 1996).